Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from
microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has
been used to treat patients that have cancers that require arginine. In this study, ADI will
be combined with the well known chemotherapy cisplatin, and the safety and potential efficacy
of this combination will be explored in patients with cancers that require arginine.